Ashok Gnxt Pharma Private Limited - Due diligence report

A 360° intelligence report on Ashok Gnxt Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth a…

2019-04-02 Vadodara, Gujarat Active Unlisted
Share
Connect MCP
AG Ashok Gnxt Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Ashok Gnxt Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
59/100
Trust Score
Moderate

Ashok Gnxt Pharma Private Limited is assessed as Moderate with a Trust Score of 59/100. Ashok Gnxt Pharma Private Limited is an active private limited indian non-government company incorporated in 2019, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 02 Aug 2026 from the latest processed filings. Ashok Gnxt Pharma Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
59/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
82/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
10/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
30/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Working-capital cover adequate.

Charges position: 1 open (3.00 cr) · 1 satisfied (1.65 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited2 48.0 cr
Compliance Score: 82/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 auditor resignation(s) filed - latest: SHAH GANDHI & SHAH on 2022-03-29.
  • Delayed payments to MSME suppliers disclosed (24 disclosure(s)).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SAMIR JAYANTILAL SHAH 01234567 Director 01/04/2018 6 yrs Approved
ROHAN MAHESH SHAH 01234567 Director 01/04/2018 6 yrs Approved
MAHESH KANTILAL SHAH 01234567 Director 01/04/2018 6 yrs Approved
Yusuke Kumaki 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Skites Pharma Private Limited
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 11 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Skites Pharma Private Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 50 · Distress 30
Growth signals & trust indicators
Asset base grew 38% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 7 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Outside liabilities up 1.42 in a year.
Negative net worth.
1 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 2.21 Lakh.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence60/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 4 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment44/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 3.00 cr already registered.
  • Compliance record supports lending.
Investor view38/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
25 Sep 2025
Last AGM held
Annual general meeting
27 Jun 2025
Director appointed
Yusuke Kumaki (Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
02 Dec 2022
Director ceased
SAMIR JAYANTILAL SHAH
Director ceased
EISHI MAEKAWA
Director ceased
ROHAN MAHESH SHAH
Director ceased
MAHESH KANTILAL SHAH
21 Jun 2022
Charge created
Hdfc Bank Limited - 3.00 cr
31 Mar 2022
Share transfer (FY 2022)
3400.00000000 shares to Skites Pharma Private Limited
Share transfer (FY 2022)
199.00000000 shares to Skites Pharma Private Limited
Share transfer (FY 2022)
3100.00000000 shares to Skites Pharma Private Limited
Share transfer (FY 2022)
1513.00000000 shares to Skites Pharma Private Limited
Share transfer (FY 2022)
757.00000000 shares to Skites Pharma Private Limited
Share transfer (FY 2022)
515.00000000 shares to Skites Pharma Private Limited
Share transfer (FY 2022)
1.00000000 shares to Samir J. Shah On behalf of Skites Pharma Private Limited
10

Key Observations

Auto-generated from the data above
Revenue declined 2.1x over the last 3 financial year(s).
Net profit margin moved from 24% to 0.86.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Rudraksh Minechem Private Limited U24231GJ1997PTC031577 Gandhidham, Gujarat, India
Hipolin L24240GJ1994PLC021719 Ahmedabad, Gujarat, India
Molecules Conchem Private Limited U24306HR2016PTC065366 Jind, Haryana, India
Tetra India Private Limited U29297HR2008PTC038583 Bawal, Haryana, India
Kaisha Lifesciences U74120MH2010PTC205291 Mumbai, Maharashtra, India
Medilife Impex Private Limited U51101MH2012PTC228514 Hingna, Maharashtra, India
Shri Ramkripa Organics Private Limited U24119RJ2005PTC020602 Distt Alwar, Rajasthan, India
Sree Ramu Speciality Surfactants Private Limited U24240PY2015PTC003028 Puducherry, Pondicherry, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Ashok Gnxt Pharma Private Limited before audits and certifications: compliance score 82/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Ashok Gnxt Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 50/100, margin trends, ownership structure and peer set for Ashok Gnxt Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 59/100, distress signals and MSME payment-delay disclosures - know whether Ashok Gnxt Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Ashok Gnxt Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Ashok Gnxt Pharma Private Limited an active company?

Ashok Gnxt Pharma Private Limited has MCA status “Active” with a compliance score of 82/100 (Low Risk).

Is Ashok Gnxt Pharma Private Limited financially healthy?

Ashok Gnxt Pharma Private Limited has a Financial Health Score of 10/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Ashok Gnxt Pharma Private Limited?

Its overall Trust Score is 59/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Ashok Gnxt Pharma Private Limited?

The ultimate holding entity is Skites Pharma Private Limited. 4 active director(s) are on record.

Does Ashok Gnxt Pharma Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Ashok Gnxt Pharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 82/100 (Low Risk).

Is it risky to lend to Ashok Gnxt Pharma Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.